Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 3;4(4):408-415.
doi: 10.21873/cdp.10340. eCollection 2024 Jul-Aug.

Prognostic Role of Platelet-to-Lymphocyte and Neutrophil-to-Lymphocyte Ratios in Patients Irradiated for Glioblastoma Multiforme

Oksana Zemskova  1   2 , Nathan Y Yu  3 , Anastassia Löser  1 , Jan Leppert  4 , Dirk Rades  1
Affiliations

Prognostic Role of Platelet-to-Lymphocyte and Neutrophil-to-Lymphocyte Ratios in Patients Irradiated for Glioblastoma Multiforme

Oksana Zemskova et al. Cancer Diagn Progn. .

Abstract

Background/aim: Previous studies suggested pre-operative platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) to be predictive factors in patients with glioblastoma multiforme (GBM). This study investigated the prognostic role of PLR and NLR prior to or at the beginning of radiotherapy.

Patients and methods: In 80 patients with GBM receiving conventionally fractionated radiotherapy plus concurrent temozolomide following resection or biopsy, 12 factors including PLR and NLR were retrospectively evaluated regarding progression-free survival (PFS) and overall survival (OS).

Results: On multivariable analyses, PLR ≤150, Karnofsky performance score (KPS) 90-100, and O6-methylguanine-DNA methyltransferase promoter methylation were significantly associated with improved PFS. Single lesion, KPS 90-100, and adjuvant chemotherapy were significantly associated with OS; PLR ≤150 showed a trend. NLR ≤3 showed a trend for associations with PFS and OS on univariable analyses.

Conclusion: PLR prior to or at the beginning of radiotherapy was associated with treatment outcomes in patients irradiated for GBM and should be considered in future clinical trials.

Keywords: Glioblastoma multiforme; irradiation; overall survival; platelet-to-lymphocyte ratio; progression-free survival.

PubMed Disclaimer

Conflict of interest statement

The Authors report no conflicts of interest related to this study.

Figures

Figure 1
Figure 1. Comparison of platelet-lymphocyte ratio (PLR) ≤150 vs. PLR >150 with respect to progression-free survival (PFS).
Figure 2
Figure 2. Comparison of platelet-lymphocyte ratio (PLR) ≤150 vs. PLR >150 with respect to overall survival (OS).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Anton K, Baehring JM, Mayer T. Glioblastoma multiforme. Hematol Oncol Clin North Am. 2012;26(4):825–853. doi: 10.1016/j.hoc.2012.04.006. - DOI - PubMed
    1. Lv Y, Zhang S, Liu Z, Tian Y, Liang N, Zhang J. Prognostic value of preoperative neutrophil to lymphocyte ratio is superior to systemic immune inflammation index for survival in patients with Glioblastoma. Clin Neurol Neurosurg. 2019;181:24–27. doi: 10.1016/j.clineuro.2019.03.017. - DOI - PubMed
    1. Rades D, Schild SE. Personalization of radiation therapy in the primary treatment of malignant epidural spinal cord compression (MESCC) Semin Radiat Oncol. 2023;33(2):148–158. doi: 10.1016/j.semradonc.2022.11.005. - DOI - PubMed
    1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. doi: 10.1056/NEJMoa043330. - DOI - PubMed
    1. Fabian D, Guillermo Prieto Eibl MDP, Alnahhas I, Sebastian N, Giglio P, Puduvalli V, Gonzalez J, Palmer JD. Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): a review. Cancers (Basel) 2019;11(2):174. doi: 10.3390/cancers11020174. - DOI - PMC - PubMed

LinkOut - more resources